Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01178216 · ClinicalTrials.gov registry record · Phase 1
Use of Immune Globulin Plus Rituximab for Desensitization in Highly HLA Sensitized Patients Awaiting Deceased Donor Kidney Transplantation
A Phase 1 study of End Stage Renal Disease, sponsored by Stanley Jordan, MD.
- Completed
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
- 1
- Study location
NCT01178216 is a Phase 1 study of End Stage Renal Disease that has completed, run by Stanley Jordan, MD. The registered enrollment target is 41 participants, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01178216, a Phase 1 study of End Stage Renal Disease, has completed, sponsored by Stanley Jordan, MD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
- 1
- Study location
Study Summary
This single center, Phase I/II, exploratory study has been modified to a safety/efficacy study providing all patients with IVIG and Rituximab. The trial will examine the safety and efficacy of human polyclonal IVIG 10%, when given at \[2.0 gm/kgx2\], + Rituximab 1gm to reduce donor-specific antibodies (DSA) to a level that is permissive for transplantation in 75 subjects (adults only ages \>18 yrs) who are highly-HLA sensitized and are awaiting deceased donor kidney transplant. Once transplant offers are entertained, a donor-specific crossmatch will be performed. If acceptable crossmatches and DSA levels are seen, the patients will proceed to DD transplantation. Patients receiving transplants will receive an additional dose of IVIG at transplantation (within 10 days) and will receive additional doses of Rituximab 1g at 3M post transplant if DSA levels remain or become positive at 6M if de novo DSA occur. Patients who are desensitized and not transplanted at 9M after desensitization will have completed the study and can be treated as best judged by their physician.
Conditions Studied
Interventions
- BIOLOGICAL Rituxan
Study Locations (1)
California
- Cedars-Sinai Medical Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2013-09 |
| Est. Completion | 2017-07-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01178216
The ClinicalTrials.gov registry entry for NCT01178216 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (95% lower). The listed sponsor is Stanley Jordan, MD, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with End Stage Renal Disease appearing as the primary indexed condition, and to 1 intervention - of which Rituxan is the first listed.
NCT01178216 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01178216 about?
NCT01178216 is a clinical study titled "Use of Immune Globulin Plus Rituximab for Desensitization in Highly HLA Sensitized Patients Awaiting Deceased Donor Kidney Transplantation". This single center, Phase I/II, exploratory study has been modified to a safety/efficacy study providing all patients with IVIG and Rituximab. The trial will examine the safety and efficacy of human polyclonal IVIG 10%, when given at \[2.0 gm/kgx2\], + Rituximab 1gm to reduce donor-specific antibodi...
What is the current status of trial NCT01178216?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2013-09. Estimated completion is 2017-07-28.
What conditions does trial NCT01178216 study?
This clinical trial studies the following conditions: End Stage Renal Disease.
What interventions are being tested in trial NCT01178216?
The interventions under investigation include: Rituxan (BIOLOGICAL).
Who is sponsoring clinical trial NCT01178216?
This trial is sponsored by Stanley Jordan, MD, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01178216 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for End Stage Renal Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
AMSC for Reducing Anastomotic Stenosis in Primary Arteriovenous Anastomoses
RECRUITING · Phase 1
-
A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)
RECRUITING · Phase 1
-
Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant
ACTIVE NOT RECRUITING · Phase 1
-
C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI
COMPLETED · Phase 1
-
Plazomicin Study in ESRD Patients Receiving IHD
COMPLETED · Phase 1
-
A Study to Evaluate the Effect of Renal Function on the Biological Activity of Telavancin
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.